NASDAQ · GEHC
GE HealthCare Technologies Inc.
Healthcare · Medical - Devices
$71.45▲ 0.10% ($0.07)at close
Pre-market$71.60▲ 0.21%7:15 AM ET
Valuation
Cash-flow DCF
Verdict: fairly priced. Price above Base.
The price holds with free cash flow shrinking 3.0% a year for 5 years. Our scenarios assume −11.7–10.4%.
Its past 5 years averaged −4.6% a year.
Value per share
Base case
$65.07
Price used $71.45 is 10% above this
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
1 more note
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
Free cash flow each value needs
Free cash flow today $2.2B. The price needs $2.2B by 2036. Base case: $2.1B. At its recent pace: $1.4B. Bear to Bull: $1.4B to $4.8B.
Free cash flow today $2.2B. The price needs $2.2B by 2036. Base case: $2.1B. At its recent pace: $1.4B. Bear to Bull: $1.4B to $4.8B.
Free cash flow in 2036
today $2.2B
+$175Mmore than the Base case · 1.1×
Value per share · Base case
$65.07
Price $71.45
10% above this
- Stage 1 growth, yrs 1–5
- −4.6%
- Stage 2 growth, yrs 6–10
- 3.5%
- Discount rate
- 7.3%
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
1 more note
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
USD · TTM ending Jun 30, 2026 · Price Oct 23, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 7.52% over the last year. Revenue grew 1.39% over the trailing twelve months. Operating margin moved from 13.82% to 12.7%. Free cash flow declined 42.81% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 12.7%. A decisive move in revenue — currently up 1.39% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
11
Buy
8
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Oct 28, 2026
Q3 FY26 · EPS est $1.20 · Revenue est $5.4B
Same quarter, year over year
FY26 YTD +2.4%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $2.12 vs $2.07 · 1 of 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $4.58
- +2.0%
- FY24
- $4.49
- —
Q2 FY26
Reported Jul 29, 2026 · Latest
HoverTap a cell to inspect
Actual
$1.13
Estimate
$1.04
Year over year
+6.6%
Vs prior quarter
+14.1%
Institutional Sentiment
GE HealthCare Technologies Inc. · GEHC
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.